NFL Biosciences SA (EPA:ALNFL)

Market Cap	11.53M -31.0%
Revenue (ttm)	188.00 +308.7%
Net Income	-3.32M
EPS	n/a
Shares Out	12.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,281
Average Volume	43,163
Open	0.8850
Previous Close	0.9100
Day's Range	0.8440 - 0.8950
52-Week Range	0.8440 - 1.8460
Beta	1.15
RSI	25.01
Earnings Date	Apr 15, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL

Financial Performance

In 2025, NFL Biosciences's revenue was 188, an increase of 308.70% compared to the previous year's 46. Losses were -3.32 million, 59.5% more than in 2024.